Farnesoid X receptor represses hepatic human APOA gene expression.
about
Human Genetics and the Causal Role of Lipoprotein(a) for Various DiseasesFarnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivoEffect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetesRelook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population.Nutrient-sensing nuclear receptors coordinate autophagy.Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population.Identification and validation of N-acetyltransferase 2 as an insulin sensitivity geneBile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.Lipoprotein(a) metabolism: potential sites for therapeutic targets.Transcriptional coordination of hepatic autophagy by nutrient-sensing nuclear receptor PPARα and FXR.Lipoprotein(a): resurrected by genetics.Update on lipoprotein(a) as a cardiovascular risk factor and mediator.Critical review of non-statin treatments for dyslipoproteinemia.Lipoprotein(a) as a therapeutic target in cardiovascular disease.Targeting lipoprotein (a): an evolving therapeutic landscape.Pathobiology of Lp(a) in calcific aortic valve disease.Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.Lipoprotein (a): a historical appraisal.Nat1 Deficiency Is Associated with Mitochondrial Dysfunction and Exercise Intolerance in Mice.Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.Diallyl disulphide inhibits apolipoprotein(a) expression in HepG2 cells through the MEK1-ERK1/2-ELK-1 pathway.Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.The Bile Acids, Deoxycholic Acid and Ursodeoxycholic Acid, Regulate Colonic Epithelial Wound Healing.Identification of functional farnesoid X receptors in brain neurons.miR-23b-3p and miR-125b-5p downregulate apo(a) expression by targeting Ets1 in HepG2 cells.Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.H2 S inhibits apo(a) expression and secretion through PKCα/FXR and Akt/HNF4α pathways in HepG2 cells.
P2860
Q28079294-E5F6F69C-4B58-44DE-97FF-98D2D015AF72Q28296042-8837091E-BEB0-47FA-8DF3-C4891B164B26Q33654017-FFD13DA2-DEFB-48F6-9F75-4936626A4590Q34002189-1BE77AE7-F10B-4247-B4BD-149B834C4DE9Q34713459-0290B9B0-D0BB-43CA-8B43-5133C8FD1D91Q35217061-905F88F5-08D8-4C4E-9D15-B138DEE53D16Q35535617-26C9B7F8-2517-4323-91ED-BC9A6CB7C068Q36145170-9865D2B3-E99C-451F-9277-9408061472CDQ36268257-4187A4EF-B886-4293-80EB-D44229957DFFQ36302760-C77FDE09-5387-430A-938A-B87E088AA507Q36469043-5FEEA422-636E-4EED-A087-B01F812D939CQ36539756-3A98CFD6-9AA0-4CD8-B28B-D450770F12FEQ37622448-8BAE20B8-E581-4469-B9D6-918A16D54AF5Q38045424-8F0C6FC2-C080-47A5-9CF6-5AC5D02A66E4Q38132701-D37F59B9-3D2C-41C7-93F0-9E3CA8E1B00BQ38186099-14EF9D12-EB5C-4E13-816E-AF6AEC465B5CQ38213476-3ED104F3-4086-4BB1-BED4-E86C2FD6970EQ38367355-4547E40C-F48B-4BD1-AEAD-A8FC30B313A9Q38620736-46C7962E-E5B0-4653-B521-600D44F39330Q38727796-E17C5D09-FBDA-4419-B71C-9BDDD3C38231Q39002143-86E760ED-77F4-4C77-A45E-518698FF482EQ42373308-6832CD44-80C3-4D34-BC26-451BC6B48BCCQ46239308-4E4D414B-393D-4241-B9CD-87D224BECB86Q47160188-23B4A23B-EFD4-4941-984E-F7601096F6FEQ47274864-D2D2D528-DB02-4B5C-9395-759F41BA58AFQ47651605-B6CEA348-9A80-474A-B6A4-4B1A0E645B86Q48559958-6218D676-BC38-4E8A-A363-4D19E3EE2B5CQ50075849-E3AE2E53-98B9-419F-80AC-C7239362F12DQ50157113-2634623C-79E3-4588-A4C4-4A2674BB37EBQ51704332-F6CD7DB5-3D14-4671-830C-815370E5F0F9
P2860
Farnesoid X receptor represses hepatic human APOA gene expression.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Farnesoid X receptor represses hepatic human APOA gene expression.
@ast
Farnesoid X receptor represses hepatic human APOA gene expression.
@en
type
label
Farnesoid X receptor represses hepatic human APOA gene expression.
@ast
Farnesoid X receptor represses hepatic human APOA gene expression.
@en
prefLabel
Farnesoid X receptor represses hepatic human APOA gene expression.
@ast
Farnesoid X receptor represses hepatic human APOA gene expression.
@en
P2093
P2860
P356
P1476
Farnesoid X receptor represses hepatic human APOA gene expression.
@en
P2093
Anna Baghdasaryan
Dagmar Kratky
Frank J Gonzalez
Gert M Kostner
Indumathi Chennamsetty
Karam M Kostner
Michael Trauner
Sanja Levak-Frank
Sasa Frank
Thierry Claudel
P2860
P304
P356
10.1172/JCI45277
P407
P577
2011-08-01T00:00:00Z